Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2026-03-03 @ 6:36 AM
Study NCT ID:
NCT01875666
Status:
COMPLETED
Last Update Posted:
2020-09-04
First Post:
2013-06-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-08-05
Start Date Type:
ACTUAL
Primary Completion Date:
2016-12-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-12-19
Completion Date Type:
ACTUAL
First Submit Date:
2013-06-04
First Submit QC Date:
None
Study First Post Date:
2013-06-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-09-03
Last Update Post Date:
2020-09-04
Last Update Post Date Type:
ACTUAL